国际放射治疗临床试验认证中IMRT剂量审计敏感性与特异性比较
该研究比较了六家GHG成员组织用于IMRT临床试验认证的端到端剂量审计系统。基于16个头颈部参考计划生成的144个修改计划,各审计系统以自身模体和标准流程测量无误差计划,并与修改计划剂量计算比较。所有系统均能可靠识别失败计划(敏感度0.92-1.0,特异度0.40-0.91),但各系统调校的误差阈值不同(3.3%-5.7%)。
要点
- 所有审计系统在5% ΔCTVmean行动阈值下敏感度达0.92-1.0,均能可靠识别失败计划。
- 各审计系统调校的误差检测阈值不同,范围为3.3%-5.7%。
- 基于敏感度可在国际范围协调剂量审计,特异度协调有待未来工作。
核心结论
- 所有审计系统敏感度相近且较高,可仅基于敏感度在国际范围协调临床试验剂量审计。
- 未来协调特异度将有助于简化国际临床试验的认证流程。
研究设计与样本
- 基于16个已建立并验证的头颈部参考计划,引入来自临床实践报道变异的现实修改,生成144个修改计划。
- 使用计划评估指标及CTVmean、CTVD95和OARD0.03cc的行动限将计划分为可接受(应通过)和不可接受(应失败)。
- 各GHG审计系统以自身模体和标准工作流程测量无误差参考计划,再与修改计划的剂量计算比较。
- 结果以通过/失败表示,与「应通过/应失败」基准比较以确定各系统的敏感度和特异度。
- 为每个审计系统确定最佳行动限以实现所有系统共同的敏感度。
主要发现
- 在5% ΔCTVmean评估行动阈值下,所有审计系统可靠识别失败计划,敏感度0.92-1.0,特异度0.40-0.91。
- 调整行动限显示各审计系统调校的误差检测阈值不同,范围为3.3%-5.7%。
- 改变审计系统行动限可改变特异度,同时保持系统敏感度。
关键数值与推荐
- 敏感度0.92-1.0,特异度0.40-0.91,对应5% ΔCTVmean评估行动阈值。
- 各审计系统调校的误差检测阈值范围为3.3%-5.7%。
- 计划分类依据CTVmean、CTVD95和OARD0.03cc的计划评估指标及行动限。
临床怎么用
- 国际多中心临床试验可基于敏感度协调剂量审计,减少审计重叠。
- 各审计系统需注意自身调校的误差检测阈值不同(3.3%-5.7%)。
- 未来协调特异度可进一步简化国际临床试验认证流程。
局限性
- 研究基于头颈部参考计划,未涉及其他解剖部位。
- 特异度协调尚未完成,当前仅实现基于敏感度的协调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Assess consistency of end-to-end dosimetry audits used by six Global Quality Assurance of Radiation Therapy Clinical Trials Harmonization Group (GHG) member organizations to harmonise audits and reduce audit overlap in multinational trials while maintaining quality. METHODS: Prior work developed and validated 16 head and neck reference plans, based on established international dosimetry audits for intensity modulated radiotherapy treatments. Realistic modifications, developed from reported variations in clinical practice, were introduced into nine copies of each plan, generating 144 modified plans. These plans were grouped as acceptable (should pass) and unacceptable (should fail) using plan assessment metrics and action limits on CTVmean, CTVD95, and OARD0.03cc. In the current work, each GHG audit system measured the error-free reference plans on its own phantom using its standard workflow. The measured error-free plans were then compared to the dose calculations of the modified plans. Outcomes were expressed as pass/fail, which were then compared to the "should pass/should fail" benchmark to determine the sensitivity and specificity of each system. An optimal action limit was determined for each audit system to achieve a common sensitivity across all audit systems. RESULTS: All audit systems reliably identified failing plans (sensitivity 0.92-1.0; specificity 0.40-0.91) with 5% ΔCTVmean assessment action thresholds. Adjusting the action limit revealed that each audit system was tuned to detect different error thresholds (3.3% - 5.7%). Changing audit system action limits specificity, while preserving system sensitivity. CONCLUSION: The comparably high sensitivity across all audit systems could allow harmonising of dosimetry audits for clinical trials on an international scale based on sensitivity alone. Future work harmonising specificity would help streamline credentialing for international clinical trials.
引用
- Brooks F, Lehmann J, Hussein M, et al. A comparison of sensitivity and specificity of dosimetry audits for intensity modulated radiation therapy used internationally for clinical trial credentialing. Radiother Oncol. 2026. PMID: 41638318. doi:10.1016/j.radonc.2026.111407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。